PPIDT00376
Drug Information
| Name | Emicizumab |
|---|---|
| Sequence | QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQKEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNRYTQKSLSLSP |
| DrugBank_ID | DB13923 |
| Type | biotech |
| Indication | The main function of Emicizumab is the prevention of bleeding episodes. Thus, Emicizumab is approved for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes of adult and pediatric patients with hemophilia A with or without Factor VIII inhibitors.[L4657] Hemophilia A is a deficiency of coagulation Factor VIII which causes a serious bleeding disorder. The standard treatment is done with the administration of recombinant or serum-deriver Factor VIII which induces the formation of anti-factor VIII alloantibodies (Factor VIII inhibitors) and renders the standard treatment ineffective.[A31286] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
30 MG/ML
|
| Injection, solution | Parenteral; Subcutaneous |
150 MG/ML
|
| Injection, solution | Parenteral; Subcutaneous |
30 MG/ML
|
| Injection, solution | Subcutaneous |
105 mg/0.7mL
|
| Injection, solution | Subcutaneous |
12 mg/0.4mL
|
| Injection, solution | Subcutaneous |
150 mg/1mL
|
| Injection, solution | Subcutaneous |
30 mg/1mL
|
| Injection, solution | Subcutaneous |
300 mg/2mL
|
| Injection, solution | Subcutaneous |
60 mg/0.4mL
|
| Solution | Subcutaneous |
105 mg / 0.7 mL
|
| Solution | Subcutaneous |
150 mg / mL
|
| Solution | Subcutaneous |
30 mg / 1 mL
|
| Solution | Subcutaneous |
60 mg / 0.4 mL
|
| Injection, solution | Subcutaneous |
|
| Injection, solution | Subcutaneous |
150 mg/ml
|
| Injection, solution | Subcutaneous |
30 mg/mL
|
| Solution | Subcutaneous |
150 mg
|
| Solution | Subcutaneous |
15000000 mg
|
| Solution | Subcutaneous |
3000000 mg
|
| Injection, solution | — |
150 mg/1ml
|
| Injection, solution | — |
30 mg/1ml
|